Seeking Alpha
04 Jul 2026, 06:06 UTC · 19w ago
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential
Impact · against what's priced in
Candel Therapeutics (CADL) is a strong buy candidate following positive Phase III results for CAN-2409 and an extended cash runway. The transition toward a BLA filing significantly reduces clinical binary risk and establishes a clear path to commercialization.
- CADL+0.80
No priced-in read yet
- In context
Positive Phase III results in localized prostate cancer and a financial runway extended into Q1 2028 provide immediate catalysts for valuation rerating.
Read from the article alone

Search tags




